- Home
- VIGL vs DIT Comparison
VIGL vs DIT Comparison
Compare VIGL & DIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- DIT
- Stock Information
- Founded
- VIGL 2020
- DIT 1981
- Country
- VIGL United States
- DIT United States
- Employees
- VIGL N/A
- DIT N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- DIT Food Distributors
- Sector
- VIGL Health Care
- DIT Consumer Discretionary
- Exchange
- VIGL Nasdaq
- DIT Nasdaq
- Market Cap
- VIGL 89.3M
- DIT 78.7M
- IPO Year
- VIGL 2022
- DIT 1995
- Fundamental
- Price
- VIGL $1.77
- DIT $119.00
- Analyst Decision
- VIGL Strong Buy
- DIT
- Analyst Count
- VIGL 5
- DIT 0
- Target Price
- VIGL $16.33
- DIT N/A
- AVG Volume (30 Days)
- VIGL 163.1K
- DIT 222.0
- Earning Date
- VIGL 03-13-2025
- DIT 04-17-2025
- Dividend Yield
- VIGL N/A
- DIT 0.85%
- EPS Growth
- VIGL N/A
- DIT N/A
- EPS
- VIGL N/A
- DIT 5.93
- Revenue
- VIGL N/A
- DIT $2,202,495,291.00
- Revenue This Year
- VIGL N/A
- DIT N/A
- Revenue Next Year
- VIGL N/A
- DIT N/A
- P/E Ratio
- VIGL N/A
- DIT $19.81
- Revenue Growth
- VIGL N/A
- DIT 7.62
- 52 Week Low
- VIGL $1.49
- DIT $107.21
- 52 Week High
- VIGL $6.06
- DIT $184.00
- Technical
- Relative Strength Index (RSI)
- VIGL 37.23
- DIT 42.52
- Support Level
- VIGL $1.65
- DIT $107.21
- Resistance Level
- VIGL $1.94
- DIT $125.48
- Average True Range (ATR)
- VIGL 0.15
- DIT 3.65
- MACD
- VIGL -0.01
- DIT -0.47
- Stochastic Oscillator
- VIGL 22.51
- DIT 54.99
Stock Price Comparison Chart: VIGL vs DIT
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About DIT AMCON Distributing Company
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores, and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.